Pharmaceutical Company Held Quality Analysis Meeting
On the afternoon of August 31, the pharmaceutical company held the 2016 quality analysis meeting to analyze the current situation of quality management and deploy the next quality management work.
The meeting was presided over by Zhang Weidong, quality director of the pharmaceutical company. Zhang Weidong analyzed the current domestic increasingly severe regulatory situation and the current situation of quality management in pharmaceutical companies, and arranged the next step of quality management work. At the same time, he also made a summary analysis of the drug GMP inspection reports of the State Food and Drug Administration and the Provincial Food and Drug Administration from 2015 to 2016 and the defective clauses therein, listed the serious defects and major defects in each inspection report, and arranged various departments to conduct a self-examination to check and fill the defects in the defective clauses and find out the deficiencies.
At the meeting, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, put forward the 16-character requirement of "recognizing the situation, facing the reality, making a difference, and improving the level" for the quality work of the pharmaceutical company. He pointed out that the high pressure situation in the pharmaceutical production industry has only increased, and the successive introduction of generic drug quality and efficacy consistency evaluation work, drug production enterprise data reliability, drug production process verification work, eye drops special inspection and various intensive flight inspections are both risks and opportunities for enterprises. Pharmaceutical companies should seize the opportunity to improve product quality through consistency evaluation and process improvement, introduce EU and FDA certification, and strive for products to go abroad as soon as possible.
The heads of the product development department, production technology department and quality assurance department of the pharmaceutical company, the deputy director and above of the workshops of each branch factory, and the on-site QA attended the meeting. (Huang Lingxiao)